Bovilis Cryptium
Active substance
ATC code
Species
Cattle (pregnant heifers and cows).
Indications
For active immunisation of pregnant heifers and cows to raise antibodies in their colostrum against Gp40 of Cryptosporidium parvum, intended for passive immunisation of calves to reduce clinical signs (i.e., diarrhoea) caused by C. parvum.
Newborn calves:
Onset of immunity: Passive immunity commences from the start of colostrum feeding.
Duration of immunity: In calves that receive colostrum and transition milk as indicated and which were challenged at birth, passive immunity has been demonstrated until 2 weeks of age.
Dose to be administered and administration route
Subcutaneous use.
Administer the vaccine in the side of the neck.
Allow the vaccine to reach room temperature before use.
Shake well before and occasionally during use to ensure homogeneity of the vaccine prior to administration.
Common aseptic procedures should be used during vaccination.
Only sterile syringes and needles should be used.
Use of a multidose applicator is recommended when vaccinating multiple animals.
One dose: 2 ml.
Primary vaccination consists of 2 doses, 4 to 5 weeks apart, in the third trimester of pregnancy. To be completed at least 3 weeks before calving. These doses are preferably administered at different sides of the animal.
Revaccination consists of 1 dose in the third trimester of each next pregnancy. To be completed at least 3 weeks before calving.
Adverse reactions
Cattle (pregnant heifers and cows):
|
Very common (>1 animal / 10 animals treated): |
Injection site swelling1, injection site pain, injection site warmth, injection site granuloma. Elevated temperature2. |
|
Uncommon (1 to 10 animals / 1,000 animals treated): |
Muscle inflammation3. Injection site abscess4. |
1 Mean size up to 14 cm, maximum size up to 40 cm, swellings reduce in size over time, but may persist as chronic granulomatous inflammation extending from the injection site for at least 125 days.
2 Mean increase up to 1 °C with a maximum of 1.8 °C, returning to normal on ultimately the 2nd day after vaccination.
3 Granulomatous haemorrhagic inflammatory reaction in dermal and subdermal tissues with inflammation extending into the underlying muscular tissue.
4 An abscess up to 1 cm in diameter detected in the neck after the 3rd vaccination.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See the package leaflet for respective contact details.
